Michael Kelly
Director/Board Member at PRIME MEDICINE, INC.
Net worth: 1 M $ as of 2024-03-30
Profile
Mr. Michael A.
Kelly is an Independent Director at Prime Medicine, Inc., an Independent Director at Amicus Therapeutics, Inc., an Independent Director at DMC Global, Inc., a Lead Independent Director at NeoGenomics, Inc. and a President at Sentry Hill Partners LLC.
He is on the Board of Directors at Chroma Medicine, Inc., Prime Medicine, Inc., Amicus Therapeutics, Inc., DMC Global, Inc., NeoGenomics, Inc., NeoGenomics Laboratories, Inc. and Hookipa Biotech AG.
Mr. Kelly was previously employed as an Independent Director by Aprea Therapeutics, Inc., an Independent Director by HOOKIPA Pharma, Inc., a Senior Vice President-Global Business Services by Amgen, Inc., a Chief Financial Officer by Tanox, Inc., a Vice President-Finance & Controller by Biogen Idec, Inc., a Chief Financial Officer & Vice President-Finance by Nutrasweet Kelco Co. Ltd., a Chief Financial Officer & Vice President by The NutraSweet Co., a Principal by Onyx Capital Management LLC, and a Chief Financial Officer by Monsanto Life Sciences Co. He also served on the board at Direct Relief.
He received his undergraduate degree from Florida A&M University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-06-07 | 40,207 ( 0.01% ) | 473 638 $ | 2024-03-30 | |
NEOGENOMICS, INC.
0.02% | 2023-08-09 | 20,419 ( 0.02% ) | 320 987 $ | 2024-03-30 |
DMC GLOBAL INC.
0.08% | 2024-03-20 | 16,035 ( 0.08% ) | 312 522 $ | 2024-03-30 |
HOOKIPA PHARMA, INC.
0.01% | 2023-04-03 | 5,754 ( 0.01% ) | 4 097 $ | 2024-03-30 |
PRIME MEDICINE, INC.
-.--% | 2023-06-13 | 0 ( -.--% ) | - $ | 2024-03-30 |
Michael Kelly active positions
| Companies | Position | Start |
|---|---|---|
| NEOGENOMICS, INC. | Director/Board Member | 2020-07-14 |
| DMC GLOBAL INC. | Director/Board Member | 2020-07-23 |
| AMICUS THERAPEUTICS, INC. | Director/Board Member | 2020-11-30 |
| PRIME MEDICINE, INC. | Director/Board Member | 2021-10-31 |
NeoGenomics Laboratories, Inc.
 NeoGenomics Laboratories, Inc. Medical/Nursing ServicesHealth Services NeoGenomics Laboratories, Inc. operates as a cancer diagnostics and pharma services company. It serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with diagnostic, prognostic and predictive testing. The company was founded in 2002 and is headquartered in Fort Myers, FL. | Director/Board Member | 2020-06-30 |
| Sentry Hill Partners LLC | Founder | 2017-12-31 |
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Director/Board Member | 2019-02-14 |
Chroma Medicine, Inc.
 Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | Director/Board Member | 2023-09-26 |
Former positions of Michael Kelly
| Companies | Position | End |
|---|---|---|
| HOOKIPA PHARMA INC. | Director/Board Member | 2023-04-06 |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░ ░░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Michael Kelly
| Florida A&M University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 8 |
|---|---|
| AMGEN INC. | Health Technology |
| DMC GLOBAL INC. | Industrial Services |
| BIOGEN INC. | Health Technology |
| NEOGENOMICS, INC. | Health Services |
| AMICUS THERAPEUTICS, INC. | Health Technology |
| HOOKIPA PHARMA INC. | Health Technology |
| APREA THERAPEUTICS, INC. | Health Technology |
| PRIME MEDICINE, INC. | Health Technology |
| Private companies | 10 |
|---|---|
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Health Technology |
Onyx Capital Management LLC
 Onyx Capital Management LLC Investment ManagersFinance Onyx Capital Management LLC is a New York City-based hedge fund firm. | Finance |
The NutraSweet Co.
 The NutraSweet Co. Agricultural Commodities/MillingProcess Industries The NutraSweet Co. manufactures and distributes sweetener products. The company was founded in 1965 and is headquartered in Chicago, IL | Process Industries |
Direct Relief
 Direct Relief Miscellaneous Commercial ServicesCommercial Services Direct Relief provides medical assistance to improve the quality of life for people affected by poverty, disaster, and civil unrest at home and throughout the world. Direct Relief works to support the work of healthcare providers, equipping them with the medicines, supplies and equipment. The company is headquartered in Santa Barbara, CA. | Commercial Services |
| Monsanto Life Sciences Co. | |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Health Technology |
NeoGenomics Laboratories, Inc.
NeoGenomics Laboratories, Inc. Medical/Nursing ServicesHealth Services NeoGenomics Laboratories, Inc. operates as a cancer diagnostics and pharma services company. It serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with diagnostic, prognostic and predictive testing. The company was founded in 2002 and is headquartered in Fort Myers, FL. | Health Services |
| Sentry Hill Partners LLC | |
Chroma Medicine, Inc.
Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | Health Technology |
| Nutrasweet Kelco Co. Ltd. |
- Stock Market
- Insiders
- Michael Kelly
